Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

Apogee shareholders will receive $135.11 per share in cash, valuing Apogee at approximately $10.9 billion in total equity value. Apogee insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Apogee by imposing a significant penalty if Apogee accepts a competing bid. We are investigating the conduct of the Apogee board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.